LYEL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lyell Immunopharma Inc (LYEL) is not a strong buy at this time for a beginner investor with a long-term focus. The technical indicators are neutral to bearish, the financial performance is weak with declining revenue and EPS, and there are no recent positive catalysts or significant trading signals. While analysts have provided optimistic price targets, the lack of recent news or trading sentiment and the poor financial performance suggest holding off on investment for now.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 35.049, and moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 19.731, with resistance levels at 23.112 and 26.493.
Analysts have raised price targets, with one citing promising clinical data for the company's lead therapy, Ronde-Cel, in the B-cell lymphoma market. The bull case suggests a potential 209% upside.
The company's financial performance in Q4 2025 shows significant declines in revenue (-45.45% YoY), net income (-26.68% YoY), and EPS (-49.96% YoY). There is no recent news, congress trading data, or significant insider/hedge fund activity to support a bullish sentiment.
In Q4 2025, revenue dropped to $6,000 (-45.45% YoY), net income fell to -$140.72 million (-26.68% YoY), and EPS declined to -6.86 (-49.96% YoY). Gross margin remained flat at 100%.
Analysts are optimistic, with Lucid Capital raising the price target to $39 from $32 and maintaining a Buy rating. Citizens initiated coverage with an Outperform rating and a $34 price target, citing promising clinical data and significant upside potential.
